Find out how future GLP-1 RAs will affect treatment plans
A number of novel formulations of GLP-1 receptor agonists are in development, including:
- Dual GIP and GLP-1 receptor agonists
- Oral formulations of GLP-1 RAs
- Implantable formulations that last up to 6 months
How might these new developments indluence treatment decisions? To provide a perspective on the future of GLP-1 RA therapy, both Professor Steve Baina nd Professor Michael Nauck will be joining our next journal club on Thursday 28 February. Sign up to this free, CME-accredited webinar to reserve your slot today!